A Phase 3 interventional study of Finerenone (Kerendia, BAY94-8862) and Placebo in Chronic Kidney Disease and Proteinuria, sponsored by Bayer. Active, not recruiting at 132 sites in 32 countries. Open to participants aged 6 Months to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing finerenone in Renal Insufficiency, Chronic — 14 open to participants now, 16 under way, 4 of them phase 3. finerenone · Renal Insufficiency, Chronic.
Among the 25 studies testing finerenone in Renal Insufficiency, Chronic, this one is the 7th largest by planned enrollment, is one of 3 that started in 2022, is one of 6 in phase 3, reaches primary completion later than 6 of the 15 other live ones, and was the 4th registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →14 of the 25 studies testing finerenone in Renal Insufficiency, Chronic are open now, in 12 countries. Recruiting first, the newest first:
Peter Rossing · Sites in Denmark, Germany, Spain and 1 more country
Ages 18–75
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18+
University of Aarhus · Sites in Denmark
Ages 18+
The George Institute · Sites in Australia, India, New Zealand and 2 more countries
Ages 18+
Bayer · Sites in United States, Argentina, Australia and 29 more countries
Ages 1–18
By country, each count listing its studies:
finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 6 Months to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 219 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 100 across the 25 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 25 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
49 studies in Renal Insufficiency, Chronic by Bayer: 4 open now, 8 under way, 2 of them phase 3. Of 39 finished, 4 (10%) have results posted.
Among the 49 studies in Renal Insufficiency, Chronic by Bayer, this one is the 8th largest by planned enrollment of the 32 interventional ones that give a count, is one of 9 that started in 2022, is one of 9 in phase 3, and was the 22nd registered.
Bayer’s Renal Insufficiency, Chronic studies by the year they started, since 2009.
6 of the studies testing finerenone in Renal Insufficiency, Chronic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07235891Alexandria UniversityRetinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease | 2026-12-20 |
| NCT07026539University of AarhusEffect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes. | 2026-12-31 |
| NCT07849348Peking University People's HospitalStudy on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria | 2027-02 |
| NCT07155694Washington D.C. Veterans Affairs Medical CenterRole of Finerenone in African American Veterans With Diabetic Kidney Disease | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 25 studies testing finerenone in Renal Insufficiency, Chronic, from their registry updates:
Among Bayer’s 49 in Renal Insufficiency, Chronic:
This tab as a report to print or save as PDF → With an account.
Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a condition in which a person´s kidneys leak protein into the urine.
The kidneys filter waste and fluid from the blood to form urine. In children with CKD, the kidney´s filters do not work as well as they should. This can lead to accumulation of waste and fluid in the body and proteinuria. CKD can lead to other medical problems, such as high blood pressure, also known as hypertension. Vice versa, hypertension and proteinuria can also contribute to worsening of CKD. Therefore, the treatment of CKD aims to control blood pressure and proteinuria. There are treatments available for doctors to prescribe to children with CKD and hypertension and/or proteinuria. These include "angiotensin-converting enzyme inhibitors" (ACEI) and "angiotensin receptor blockers" (ARB). Both ACEI and ARB can improve kidney function by helping the renin-angiotensin-aldosterone system (RAAS) to work normally. The RAAS is a system that works with the kidneys to control blood pressure and the balance of fluid and electrolytes in the blood. In people with CKD, the RAAS is often too active, which can stop the kidneys from working properly and cause hypertension and proteinuria. However, ACEI or ARB treatment alone does not work for all patients with CKD as they only target the angiotensin part of the renin-angiotensin-aldosterone system.
The study treatment, finerenone, is expected to help control RAAS overactivation together with an ACEI or ARB.
So, the researchers in this study want to learn more about whether finerenone given in addition to either an ACEI or ARB can help their kidney function.
The main purpose of this study is to learn more about whether finerenone added to either ACEI or ARB can help reduce the amount of protein in the participants' urine more than a placebo. A placebo looks like a treatment but does not have any medicine in it. Participants will also continue to receive their other medications.
To see how the treatment work, the doctors will take samples of the participants' urine to measure their protein levels before and during taking treatment and after their last treatment. In addition, blood samples will be taken to monitor kidney function, electrolytes and the amount of finerenone in the blood as well as for other tests.
This study will include children with CKD and proteinuria aged from 6 months up to less than 18 years. The participants will take:
Two visits are required up to 104 days, to check whether a child can take part in the treatment phase of the study. If participants qualify for the treatment phase, they will then undergo treatment for about 180 days. During this time, they will visit the study site at least 7 times. During these visits, the participants will:
The doctors will keep track of any adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.
The doctors will check the participants' health about 30 days after the participants take their last treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must have a clinical diagnosis of chronic kidney disease (CKD) at screening which is defined as
severely increased proteinuria as defined by
Participants must have stable kidney function between screening and D0 defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive finerenone treatment.
Drug: Finerenone (Kerendia, BAY94-8862)
Participants will receive placebo to finerenone.
Drug: Placebo
Finerenone in different doses, treatment duration will be 180±7 days
Placebo to finerenone, treatment duration will be 180±7 days
Percent change in Urinary protein-to-creatinine ratio (UPCR) reduction from baseline to day 180+/-7
Percent change from baseline to day 180±7 in UPCR will be calculated.
Time frame: From baseline to day 180+/-7
Number participants with treatment emergent adverse events (TEAEs)
Below sub-categories will be considered: 1. Serious Treatment Emergent Adverse Events (TEAEs) 2. TEAEs and serious TEAEs leading to discontinuation of treatment 3. Study drug related TEAEs and serious TEAEs 4. TEAEs categorized by severity (mild, moderate, severe) 5. TEAEs by maximum intensity 6. Number of participants hospitalized with hyperkalemia, 7. Number of participants discontinuing due to hyperkalemia, 8. Number of participants with hospitalization for worsening of renal function 9. Number of participants discontinuing due to worsening of renal function
Time frame: From the start of study intervention to last study intervention + 3 days (up to 190 days)
Change in serum potassium levels from baseline to day 180±7
Time frame: From baseline to day 180±7
Change in serum creatinine from baseline to day 180±7
Time frame: From baseline to day 180±7
Change in eGFR from baseline to day 180±7
Estimated glomerular filtration rate (eGFR)
Time frame: From baseline to day 180±7
Change in systolic blood pressure from baseline to day 180±7
Time frame: From baseline to day 180±7
UPCR reduction of at least 30% from baseline to day 180+/-7
Proportion of participants at day 180+/-7 with a \>=30% reduction in PUCR compared to baseline
Time frame: From baseline to day 180±7
Change in UACR from baseline to day 180±7
Urinary albumin-to-creatinine ratio (UACR)
Time frame: From baseline to day 180±7
Pharmacokinetics (PK) finerenone Cmax, md
Maximum observed finerenone concentration in plasma after multiple doses.
Time frame: Pre-dose, post-dose (1.5-5 hours after intake of intervention), up to day 180±7
Pharmacokinetics (PK) finerenone AUCτ,md
Area under the curve for finerenone concentration in plasma after multiple doses.
Time frame: Pre-dose, post-dose (1.5-5 hours after intake of intervention), up to day 180±7
Taste and texture questionnaire of the pediatric formulation
Time frame: On day 30±3 and day 180±7
Showing the first 100 of 132 sites across 32 countries. Choose a country and city above to see the rest.
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Started Mar 2022 (actual). Primary completion is estimated for Apr 2027, 60 months after the start.
Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's planned 60 months is above that.
Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Finerenone
Renal Insufficiency, Chronic →